The NOAH trial [14, 49], randomized controlled trial for HER2-positive locally advanced breast cancer or IBC, also reported that the pCR significantly related with longer overall survival in patient treated with trastuzumab. This evidence concerns the gene ERBB2 and breast carcinoma.